Anti-leukemic response of a NSAID, tolfenamic acid

Targeted Oncology

Volumn 9, Issue 2, 2014, Pages 135-144

  Sutphin, Robert M ^a,b   Connelly, Sarah F ^a   Lee, Chris M ^a   Sankpal, Umesh T ^a   Eslin, Don ^a,b   Khan, Moeez ^a,c   Pius, Hima ^a,d   Basha, Riyaz ^a,c  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b ARNOLD PALMER HOSPITAL FOR CHILDREN   (United States)

^c UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^d FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Leukemia; NSAID; Sp1; Survivin; Tolfenamic acid; Transcription factors

Indexed keywords

CASPASE 3; CASPASE 7; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; SURVIVIN; TOLFENAMIC ACID; ANTHRANILIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; BIOSYNTHESIS; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; LEUKEMIA; METABOLISM; PATHOLOGY; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA; ORTHO-AMINOBENZOATES;

EID: 84902535399     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0274-9     Document Type: Article

References (57)

1. Shah A, Coleman MP (2007) Increasing incidence of childhood leukaemia: a controversy re-examined. Br J Cancer 97(7):1009-1012. doi:10.1038/sj.bjc.6603946 (Pubitemid 47519299)
2. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, Smith FO, Reaman GH (2010) Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28(15):2625-2634. doi:10.1200/JCO.2009.27.0421
3. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277-300. doi:10.3322/caac.20073
4. Cancer Facts & Figures 2011. Atlanta GACS, cancer facts & figures for African Americans 2011-2012. Atlanta GACS
5. Attia RR, Gardner LA, Mahrous E, Taxman DJ, Legros L, Rowe S, Ting JP, Geller A, Kotb M (2008) Selective targeting of leukemic cell growth in vivo and in vitro using a gene silencing approach to diminish S-adenosylmethionine synthesis. J Biol Chem 283(45):30788-30795. doi:10.1074/jbc.M804159200
6. Cunningham L, Aplenc R (2007) Pharmacogenetics of acute lymphoblastic leukemia treatment response. Expert Opin Pharmacother 8(15):2519-2531. doi:10.1517/14656566.8.15.2519 (Pubitemid 350031291)
7. Kokkinakis DM, Brickner AG, Kirkwood JM, Liu X, Goldwasser JE, Kastrama A, Sander C, Bocangel D, Chada S (2006) Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress. Mol Cancer Res 4(8):575-589. doi:10.1158/1541-7786.MCR-05-0240 (Pubitemid 44341367)
8. Pui CH, Jeha S (2007) New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 6(2):149-165. doi:10.1038/nrd2240 (Pubitemid 46758753)
9. van Ginkel PR, Sareen D, Subramanian L, Walker Q, Darjatmoko SR, Lindstrom MJ, Kulkarni A, Albert DM, Polans AS (2007) Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin Cancer Res 13(17):5162-5169. doi:10.1158/1078-0432.CCR-07- 0347 (Pubitemid 47502085)
10. Kersey JH (1997) Fifty years of studies of the biology and therapy of childhood leukemia. Blood 90(11):4243-4251
11. Tyner JW, Jemal AM, Thayer M, Druker BJ, Chang BH (2012) Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia 26(4):623 -632. doi:10.1038/leu.2011.249
12. Safe S, Abdelrahim M (2005) Sp transcription factor family and its role in cancer. Eur J Cancer 41(16):2438-2448. doi:10.1016/j.ejca.2005.08.006 (Pubitemid 41540621)
13. Ryu S, Zhou S, Ladurner AG, Tjian R (1999) The transcriptional cofactor complex CRSP is required for activity of the enhancer-binding protein Sp1. Nature 397(6718):446-450. doi:10.1038/17141
14. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, Xiong Q, Wang B, Li XC, Xie K (2001) Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61(10):4143-4154 (Pubitemid 32720983)
15. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S (2006) Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 98(12):855-868. doi:10.1093/jnci/djj232 (Pubitemid 43923442)
16. Basha R, Baker CH, Sankpal UT, Ahmad S, Safe S, Abbruzzese JL, Abdelrahim M (2011) Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid. FrontBiosci (Schol Ed) 3:797-805
17. Chang WC, Chen BK (2005) Transcription factor Sp1 functions as an anchor protein in gene transcription of human 12(S)-lipoxygenase. Biochem Biophys Res Commun 338(1):117-121
18. Lu S, Archer MC (2010) Sp1 coordinately regulates de novo lipogenesis and proliferation in cancer cells. Int J Cancer 126:416-425
19. Yuan L, Ahn IS, Davis PF (2007) Inhibition of tyrosine phosphorylation of vascular endothelial growth factor receptors in human umbilical vein endothelial cells: a potent anti-angiogenic lipid-rich extract from shark. J Med Food 10(4):657 -661. doi:10.1089/jmf.2006.123
20. Kavurma MM, Khachigian LM (2003) Sp1 inhibits proliferation and induces apoptosis in vascular smooth muscle cells by repressing p21WAF1/Cip1 transcription and cyclin D1-Cdk4-p21WAF1/Cip1 complex formation. J Biol Chem 278(35):32537-32543. doi:10.1074/jbc.M305650200 (Pubitemid 37055691)
21. Kavurma MM, Santiago FS, Bonfoco E, Khachigian LM (2001) Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement. J Biol Chem 276(7):4964-4971. doi:10.1074/jbc.M009251200
22. Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3(1):46-54. doi:10.1038/nrc968
23. Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S, Moritz T, Laws HJ, Hanenberg H, Goebel U, Janka-Schaub GE, Mahotka C, Dilloo D (2007) Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica 92(8):1043-1050 (Pubitemid 350144210)
24. Pennati M, Folini M, Zaffaroni N (2007) Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28(6):1133-1139. doi:10.1093/carcin/bgm047 (Pubitemid 47062670)
25. Eskerod O (1994) Gastrointestinal tolerance studies on tolfenamic acid in humans and animals. Pharmacol Toxicol 75(Suppl 2):44-48
26. Perez de Castro I, Bivona TG, Philips MR, Pellicer A (2004) Ras activation in Jurkat T cells following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs only on the Golgi apparatus. Mol Cell Biol 24(8):3485-3496 (Pubitemid 38452087)
27. Garcia-Gila M, Lopez-Martin EM, Garcia-Pardo A (2002) Adhesion to fibronectin via alpha4 integrin (CD49d) protects B cells from apoptosis induced by serum deprivation but not via IgM or Fas/Apo-1 receptors. Clin Exp Immunol 127(3):455-462 (Pubitemid 34437816)
28. Basha R, Ingersoll SB, Sankpal UT, Ahmad S, Baker CH, Edwards JR, Holloway RW, Kaja S, Abdelrahim M (2011) Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 122(1):163 -170. doi:10.1016/j.ygyno.2011.03.014
29. Eslin D, Sankpal UT, Lee C, Sutphin RM, Maliakal P, Currier E, Sholler G, Khan M, Basha R (2011) Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma. Mol Carcinog. doi:10.1002/mc.21866
30. Sankpal UT, Abdelrahim M, Connelly SF, Lee CM, Madero-Visbal R, Colon J, Smith J, Safe S, Maliakal P, Basha R (2012) Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer. Prostate 72(15):1648-1658. doi:10.1002/pros.22518
31. Deveraux QL, Reed JC (1999) IAP family proteins - suppressors of apoptosis. Genes Dev 13(3):239-252 (Pubitemid 29095796)
32. Abdelrahim M, Samudio I, Smith R 3rd, Burghardt R, Safe S (2002) Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells. J Biol Chem 277(32):28815-28822. doi:10.1074/jbc.M203828200
33. Abdelrahim M, Smith R 3rd, Burghardt R, Safe S (2004) Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 64(18):6740-6749. doi:10.1158/0008-5472.CAN-04-0713 (Pubitemid 39297937)
34. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S (2006) Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. Journal of the National Cancer Institute 98(12):855 -868. doi:10.1093/jnci/djj232
35. Nakagawa Y, Yamaguchi S, Hasegawa M, Nemoto T, Inoue M, Suzuki K, Hirokawa K, Kitagawa M (2004) Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk Res 28(5):487-494. doi:10.1016/j.leukres.2003.10.013 (Pubitemid 38453061)
36. Yamamoto K, Abe S, Nakagawa Y, Suzuki K, Hasegawa M, Inoue M, Kurata M, Hirokawa K, Kitagawa M (2004) Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia. Leuk Res 28(11):1203-1211. doi:10.1016/j.leukres.2004.03.020 (Pubitemid 39243246)
37. Aravindan N, Madhusoodhanan R, Ahmad S, Johnson D, Herman TS (2008) Curcumin inhibits NFkappaB mediated radioprotection and modulate apoptosis related genes in human neuroblastoma cells. Cancer Biol Ther 7(4):569-576 (Pubitemid 351847033)
38. Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M (2009) Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 8(3):533-542. doi:10.1158/1535-7163.MCT-08-0405
39. Maliakal P, Abdelrahim M, Sankpal UT, Maliakal C, Baker CH, Safe S, Herrera LJ, Abudayyeh A, Kaja S, Basha R (2012) Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. Invest New Drugs 30(3):853-861. doi:10.1007/s10637-010-9622-0
40. Li Y, Xie M, Yang J, Yang D, Deng R, Wan Y, Yan B (2006) The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter. Oncogene 25(23):3296-3306. doi:10.1038/sj.onc.1209363 (Pubitemid 43846314)
41. Xu R, Zhang P, Huang J, Ge S, Lu J, Qian G (2007) Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun 356(1):286-292. doi:10.1016/j.bbrc.2007.02.140 (Pubitemid 46413162)
42. Chen Y, Wang X, Li W, Zhang H, Zhao C, Li Y, Wang Z, Chen C (2011) Sp1 upregulates survivin expression in adenocarcinoma of lung cell line A549. Anat Rec (Hoboken) 294(5):774-780. doi:10.1002/ar.21378
43. Mityaev MV, Kopantzev EP, Buzdin AA, Vinogradova TV, Sverdlov ED (2008) Functional significance of a putative sp1 transcription factor binding site in the survivin gene promoter. Biochemistry (Mosc) 73(11):1183-1191
44. Altieri DC (2006) The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 18(6):609-615. doi:10.1016/j.ceb.2006.08.015
45. Doolittle Helen MA, Denis T (2010) Survivin-directed anticancer therapies - a review of pre-clinical data and early-phase clinical trials. European Oncology 6(1):10-14
46. Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14(16):5000-5005. doi:10.1158/1078-0432.CCR-08-0746
47. Grossman D, Kim PJ, Schechner JS, Altieri DC (2001) Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A 98(2):635-640. doi:10.1073/pnas.230450097 (Pubitemid 32105095)
48. Obexer P, Hagenbuchner J, Unterkircher T, Sachsenmaier N, Seifarth C, Bock G, Porto V, Geiger K, Ausserlechner M (2009) Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis. Mol Biol Cell 20(7):2041-2048. doi:10.1091/mbc.E08-07-0699
49. Shankar SL, Mani S, O'Guin KN, Kandimalla ER, Agrawal S, Shafit-Zagardo B (2001) Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J Neurochem 79(2):426-436 (Pubitemid 32988959)
50. Zhang XD, Gillespie SK, Hersey P (2004) Staurosporine induces apoptosis of melanoma by both caspase-dependent and - independent apoptotic pathways. Mol Cancer Ther 3(2):187-197 (Pubitemid 39193693)
51. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30(2):193-204. doi:10.1016/j.ctrv.2003.07.007
52. Molinari M (2000) Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 33(5):261-274
53. Collins I, Garrett MD (2005) Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 5(4):366-373. doi:10.1016/j.coph.2005.04.009 (Pubitemid 40932038)
54. Craig C, Wersto R, Kim M, Ohri E, Li Z, Katayose D, Lee SJ, Trepel J, Cowan K, Seth P (1997) A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 14(19):2283-2289. doi:10.1038/sj.onc.1201064 (Pubitemid 27260720)
55. Lee YM, Lim do Y, Cho HJ, Seon MR, Kim JK, Lee BY, Park JH (2009) Piceatannol, a natural stilbene from grapes, induces G1 cell cycle arrest in androgen-insensitive DU145 human prostate cancer cells via the inhibition of CDK activity. Cancer Lett 285(2):166-173. doi:10.1016/j.canlet.2009.05.011
56. MacLachlan TK, Sang N, Giordano A (1995) Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 5(2):127-156
57. Paternot S, Bockstaele L, Bisteau X, Kooken H, Coulonval K, Roger PP (2010) Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle 9(4):689-699